Hatice Tuba Atalay

Hatice Tuba Atalay

Auto-generated profile, based on publicly available information

Hatice Tuba Atalay

Gazi University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2018 in Current Eye Research
Verified
Journal Article
Closed access
HAHatice Tuba Atalay
Hatice Tuba Atalay
FDFunda Dogruman-Al
Funda Dogruman-Al
FSFakhriddin SARZHANOV
Fakhriddin SARZHANOV
MÖMehmet Cüneyt Özmen
Mehmet Cüneyt Özmen
ATAtike Burçin Tefon
Atike Burçin Tefon
KBKamil Bilgihan
Kamil Bilgihan
Purpose: To evaluate the antiamoebic properties of photo-activated chromophore for keratitis (PACK)–corneal cross-linking (CXL) (PACK-CXL), in combination with riboflavin (0.1 and 0.25%) or rose bengal (0.1 and 0.2%), for treatment of Acanthamoeba trophozoites and cysts. Materials and Methods: Cultures of Acanthamoeba castellanii were grown in a fluid medium at a concentration of 2.7 × 105 cell/ml. PACK-CXL was used on A. castellani cells in combination with either riboflavin (0.1 and 0.25%) or rose bengal (0.1 and 0.2%). Riboflavin-containing wells were irradiated with ultraviolet-A (UVA) light (365-nm wavelength). Rose bengal-containing wells were irradiated with green light (523-nm wavelength). A power density of 9 mW/cm2 for 10 min and total irradiation dose of 5.4 J/cm2 was used for both riboflavin and rose bengal. After UVA and green light irradiation, cell viabilities were evaluated, and percentage of dead cells calculated. Results: No significant amoebicidal activity was observed following PACK-CXL/riboflavin at either concentration. PACK-CXL/rose bengal, however, was observed to be highly effective in eradicating Acanthamoeba cells at either concentration, with no significant difference observed between the two concentrations. The percentage of dead cells was 63% following treatment at either rose bengal concentration. Conclusion: PACK-CXL with rose bengal demonstrated pronounced antiamoebic activity against A.castellanii. Further in vitro and in vivo studies are needed to confirm this finding.

27 February 2020 in Current Eye Research
Verified
Journal Article
Closed access
HAHatice Tuba Atalay
Hatice Tuba Atalay
BUBetül Seher Uysal
Betül Seher Uysal
FSFakhriddin SARZHANOV
Fakhriddin SARZHANOV
SUSelma Usluca
Selma Usluca
NYNilüfer Yeşilırmak
Nilüfer Yeşilırmak
KBKamil Bilgihan
Kamil Bilgihan
Purpose: To evaluate the in vivo efficacy of rose bengal (RB)-mediated photodynamic antimicrobial therapy (PDAT) for treatment of Acanthamoeba castellanii keratitis (AK). Materials and Methods: An animal (rabbit) AK model was successfully achieved via intrastromal inoculation of a suspension of A. castellanii cells and trophozoites. Prior to RB-PDAT (pre-treatment, day-5), the severity of the induced corneal infection was graded numerically for epithelial defects, stromal edema, neovascularity, and stromal opacity/infiltration. The right eyes of rabbits (n=18) were divided equally into three groups (n=6/group): control (no treatment); 0.1% RB+518 nm irradiation (5.4 J/cm2); and 0.2% RB+518 nm irradiation (5.4 J/cm2). On post-treatment day-5, animals were euthanized, after which corneal buttons were excised and submitted for real-time polymerase chain reaction (RT-PCR) analysis. Results: Post-treatment clinical scores of the 0.1 and 0.2% RB groups indicated significant improvement compared to control group scores (pre-treatment clinical scores; 5.17±0.98, 7.50±0.62, and 6.17±0.70 and post-treatment clinical scores; 4.50±0.56, (p=0.043), 3.50±0.99 (p=0.039), 6.83±1.66 (p=0.34), respectively). RT-PCR analysis revealed that the mean cycle threshold (Ct) values were significantly higher in treated-group corneas compared to control-group corneas, with no significant differences between treated-groups (Mean Ct values; 34.33, 34.5, and 29.67 for 0.1 and 0.2% RB, and control groups). There was a statistically significant negative correlation between post-treatment clinical scores and Ct values (r=-0.474, p-value 0.047). Conclusions: Our results demonstrate that RB-PDAT is effective in decreasing the parasitic load and clinical severity of AK.

1 October 2019 in Turkish Journal of Ophthalmology
Verified
Journal Article
Closed access
MHMurat Hasanreisoglu
Murat Hasanreisoglu
HOHuseyin Baran Ozdemir
Huseyin Baran Ozdemir
KÖKaan Özkan
Kaan Özkan
MYMurat Yüksel
Murat Yüksel
ZAZeynep Aktaş
Zeynep Aktaş
GGGökhan Gürelik
Gökhan Gürelik
To evaluate the long-term results of intravitreal dexamethasone implant (DEX) for noninfectious uveitis. The study included 62 eyes of 44 patients treated with DEX implant due to noninfectious uveitis and followed up for at least a year. Best-corrected visual acuity (BCVA), central foveal thickness, intraocular pressure (IOP), vitreous haze score, indications, immunomodulatory therapy and steroid usage before/after injection, number of injections, and adverse events were analyzed retrospectively. Average follow-up was 20 months (range 12-64 months). The female/male ratio was 29/15. Mean age was 50 years (range 22-75 years). The most frequent uveitis etiologies were idiopathic (25 patients, 40.3%) and Behçet’s uveitis. (17 patients, 27.4%) The most common indication for DEX injection was cystoid macular edema together with resistant vitreous haze (26 eyes, 41.9%). Twenty-two eyes (30%) received more than one DEX injection. Mean BCVA was improved from 0.55 logMAR at baseline to 0.38, 0.32, and 0.35 after 1, 3, and 6 months, respectively (p<0.001 for each). Mean CFT was decreased from 386 μm at baseline to 288, 311, and 302 μm after 1, 3, and 6 months, respectively (p<0.001 for each). Mean IOP did not change significantly during follow-up. Five eyes (8%) received topical anti-glaucoma medication (IOP ≥25 mmHg). Eighteen (46%) of 39 phakic eyes underwent cataract surgery during follow-up. Similar efficacy of the DEX implant was observed in eyes that received multiple injections. Systemic immunomodulatory therapy did not change significantly during follow-up. Intravitreal DEX injection does not alter systemic immunomodulatory therapy, but may facilitate the management of noninfectious uveitis by suppressing local intraocular inflammation. Multiple injections yielded comparable visual and anatomical outcomes to single injections. Follow-up for ocular hypertension and cataract formation are important, especially in eyes receiving multiple injections.

15 January 2020 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
LOLeman Tekin Orgun
Leman Tekin Orgun
HAHatice Tuba Atalay
Hatice Tuba Atalay
EAEbru Arhan
Ebru Arhan
KAKursad Aydın
Kursad Aydın
ASAyse Serdaroglu
Ayse Serdaroglu

1 February 2021 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
AUAhmet Yucel Ucgul
Ahmet Yucel Ucgul
SOSengul Ozdek
Sengul Ozdek
MEMestan Ertop
Mestan Ertop
HAHatice Tuba Atalay
Hatice Tuba Atalay

1 January 2019 in Indian Journal Of Ophthalmology
Verified
Journal Article
Open access
PDF file
HAHatice Tuba Atalay
Hatice Tuba Atalay
ŞÖŞengül Özdek
Şengül Özdek
DYDuygu Yalınbaş
Duygu Yalınbaş
CÖCemal Özsaygılı
Cemal Özsaygılı
MÖMehmet Cüneyt Özmen
Mehmet Cüneyt Özmen
Purpose: To report anatomical and functional results of vitreoretinal surgery in our case series of late cicatricial retinopathy of prematurity (ROP) patients with subtotal retinal detachment. Methods: This is a retrospective, consecutive case series. Eleven eyes of 10 patients presented with partial tractional retinal detachment secondary to late cicatricial ROP (cicatricial stage 4B) who underwent vitreoretinal surgery were retrospectively reviewed. Anatomical and functional outcomes were evaluated. Results: The mean gestational age at birth was 28.6 (26–32) weeks. The mean age at surgery was 79 (4–213) months. Patients were followed up for 21.7 (6–40) months. Six eyes (55%) had lens-sparing vitrectomy and five eyes (45%) had lensectomy + vitrectomy. Anatomical success was achieved in 10 eyes (91%). Improvement in visual acuity was noted in nine eyes (82%). Conclusion: Eye grows but fibrotic tissue does not grow with age, and during this period retinal traction may get worse. Relieving these tractions may lead to good anatomical and visual outcomes in selected late cicatricial ROP cases.